Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.

Identifieur interne : 001653 ( Main/Exploration ); précédent : 001652; suivant : 001654

An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.

Auteurs : Susan Li Er Loong [Singapour] ; Jacqueline Siok Gek Hwang ; Soon-Thye Lim ; Swee Peng Yap ; Miriam Tao ; Tsung-Wen Chong ; Leonard Hwan Cheong Tan ; Hung Huynh

Source :

RBID : pubmed:18452087

Descripteurs français

English descriptors

Abstract

Natural killer (NK) lymphomas occurring more frequently in the Far East and South America respond poorly to anthracycline-based regimens. Here we report an in vivo NK lymphoma xenograft (NK-S1) derived from the testicular metastasis of a patient with an extranodal NK lymphoma (nasal type). The NK-S1 xenograft, established in severe combined immune deficient (SCID) mice retained the same imunophenotypic features as the original tumor. NK-S1 disseminated intra-abdominally to the testis, intestine and liver. Although doxorubicin, rapamycin, bevacizumab, rapamycin-doxorubicin, and bevacizumab-doxorubicin had no effects on the growth of subcutaneous NK-S1 xenografts, intraperitoneal (IP) delivery of cyclophosphamide caused complete tumor regression; this tumor regression was associated with apoptosis, upregulation of activated caspase-3, and cleaved Poly(ADP-ribose) polymerase (PARP). In an IP model of NK lymphoma, cyclophosphamide also prolonged the survival of mice and potently inhibited tumor dissemination and ascites formation. Our data suggest that the NK-S1 xenograft is a useful tool for screening preclinical drugs, and cyclophosphamide may be a useful drug for the treatment of this disease.

DOI: 10.1080/10428190802043879
PubMed: 18452087


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.</title>
<author>
<name sortKey="Loong, Susan Li Er" sort="Loong, Susan Li Er" uniqKey="Loong S" first="Susan Li Er" last="Loong">Susan Li Er Loong</name>
<affiliation wicri:level="1">
<nlm:affiliation>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre</wicri:regionArea>
<wicri:noRegion>National Cancer Centre</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Hwang, Jacqueline Siok Gek" sort="Hwang, Jacqueline Siok Gek" uniqKey="Hwang J" first="Jacqueline Siok Gek" last="Hwang">Jacqueline Siok Gek Hwang</name>
</author>
<author>
<name sortKey="Lim, Soon Thye" sort="Lim, Soon Thye" uniqKey="Lim S" first="Soon-Thye" last="Lim">Soon-Thye Lim</name>
</author>
<author>
<name sortKey="Yap, Swee Peng" sort="Yap, Swee Peng" uniqKey="Yap S" first="Swee Peng" last="Yap">Swee Peng Yap</name>
</author>
<author>
<name sortKey="Tao, Miriam" sort="Tao, Miriam" uniqKey="Tao M" first="Miriam" last="Tao">Miriam Tao</name>
</author>
<author>
<name sortKey="Chong, Tsung Wen" sort="Chong, Tsung Wen" uniqKey="Chong T" first="Tsung-Wen" last="Chong">Tsung-Wen Chong</name>
</author>
<author>
<name sortKey="Tan, Leonard Hwan Cheong" sort="Tan, Leonard Hwan Cheong" uniqKey="Tan L" first="Leonard Hwan Cheong" last="Tan">Leonard Hwan Cheong Tan</name>
</author>
<author>
<name sortKey="Huynh, Hung" sort="Huynh, Hung" uniqKey="Huynh H" first="Hung" last="Huynh">Hung Huynh</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18452087</idno>
<idno type="pmid">18452087</idno>
<idno type="doi">10.1080/10428190802043879</idno>
<idno type="wicri:Area/Main/Corpus">001615</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001615</idno>
<idno type="wicri:Area/Main/Curation">001615</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001615</idno>
<idno type="wicri:Area/Main/Exploration">001615</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.</title>
<author>
<name sortKey="Loong, Susan Li Er" sort="Loong, Susan Li Er" uniqKey="Loong S" first="Susan Li Er" last="Loong">Susan Li Er Loong</name>
<affiliation wicri:level="1">
<nlm:affiliation>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre</wicri:regionArea>
<wicri:noRegion>National Cancer Centre</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Hwang, Jacqueline Siok Gek" sort="Hwang, Jacqueline Siok Gek" uniqKey="Hwang J" first="Jacqueline Siok Gek" last="Hwang">Jacqueline Siok Gek Hwang</name>
</author>
<author>
<name sortKey="Lim, Soon Thye" sort="Lim, Soon Thye" uniqKey="Lim S" first="Soon-Thye" last="Lim">Soon-Thye Lim</name>
</author>
<author>
<name sortKey="Yap, Swee Peng" sort="Yap, Swee Peng" uniqKey="Yap S" first="Swee Peng" last="Yap">Swee Peng Yap</name>
</author>
<author>
<name sortKey="Tao, Miriam" sort="Tao, Miriam" uniqKey="Tao M" first="Miriam" last="Tao">Miriam Tao</name>
</author>
<author>
<name sortKey="Chong, Tsung Wen" sort="Chong, Tsung Wen" uniqKey="Chong T" first="Tsung-Wen" last="Chong">Tsung-Wen Chong</name>
</author>
<author>
<name sortKey="Tan, Leonard Hwan Cheong" sort="Tan, Leonard Hwan Cheong" uniqKey="Tan L" first="Leonard Hwan Cheong" last="Tan">Leonard Hwan Cheong Tan</name>
</author>
<author>
<name sortKey="Huynh, Hung" sort="Huynh, Hung" uniqKey="Huynh H" first="Hung" last="Huynh">Hung Huynh</name>
</author>
</analytic>
<series>
<title level="j">Leukemia & lymphoma</title>
<idno type="eISSN">1029-2403</idno>
<imprint>
<date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals (MeSH)</term>
<term>Antibodies, Monoclonal (administration & dosage)</term>
<term>Antibodies, Monoclonal, Humanized (MeSH)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Apoptosis (drug effects)</term>
<term>Bevacizumab (MeSH)</term>
<term>Blotting, Western (MeSH)</term>
<term>Caspase 3 (metabolism)</term>
<term>Cyclophosphamide (administration & dosage)</term>
<term>Doxorubicin (administration & dosage)</term>
<term>Enzyme Activation (drug effects)</term>
<term>Epstein-Barr Virus Infections (drug therapy)</term>
<term>Epstein-Barr Virus Infections (virology)</term>
<term>Herpesvirus 4, Human (isolation & purification)</term>
<term>Humans (MeSH)</term>
<term>Injections, Intraperitoneal (MeSH)</term>
<term>Killer Cells, Natural (drug effects)</term>
<term>Killer Cells, Natural (virology)</term>
<term>Lymphoma, T-Cell, Peripheral (drug therapy)</term>
<term>Lymphoma, T-Cell, Peripheral (virology)</term>
<term>Male (MeSH)</term>
<term>Mice (MeSH)</term>
<term>Mice, SCID (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Neoplasm Transplantation (MeSH)</term>
<term>Poly(ADP-ribose) Polymerases (metabolism)</term>
<term>Sirolimus (administration & dosage)</term>
<term>Transplantation, Heterologous (MeSH)</term>
<term>Tumor Cells, Cultured (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Activation enzymatique (effets des médicaments et des substances chimiques)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Animaux (MeSH)</term>
<term>Anticorps monoclonaux (administration et posologie)</term>
<term>Anticorps monoclonaux humanisés (MeSH)</term>
<term>Apoptose (effets des médicaments et des substances chimiques)</term>
<term>Bévacizumab (MeSH)</term>
<term>Caspase-3 (métabolisme)</term>
<term>Cellules cancéreuses en culture (MeSH)</term>
<term>Cellules tueuses naturelles (effets des médicaments et des substances chimiques)</term>
<term>Cellules tueuses naturelles (virologie)</term>
<term>Cyclophosphamide (administration et posologie)</term>
<term>Doxorubicine (administration et posologie)</term>
<term>Herpèsvirus humain de type 4 (isolement et purification)</term>
<term>Humains (MeSH)</term>
<term>Infections à virus Epstein-Barr (traitement médicamenteux)</term>
<term>Infections à virus Epstein-Barr (virologie)</term>
<term>Injections péritoneales (MeSH)</term>
<term>Lymphome T périphérique (traitement médicamenteux)</term>
<term>Lymphome T périphérique (virologie)</term>
<term>Mâle (MeSH)</term>
<term>Poly(ADP-ribose) polymerases (métabolisme)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Souris (MeSH)</term>
<term>Souris SCID (MeSH)</term>
<term>Technique de Western (MeSH)</term>
<term>Transplantation hétérologue (MeSH)</term>
<term>Transplantation tumorale (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Antibodies, Monoclonal</term>
<term>Cyclophosphamide</term>
<term>Doxorubicin</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Anticorps monoclonaux</term>
<term>Cyclophosphamide</term>
<term>Doxorubicine</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Apoptosis</term>
<term>Enzyme Activation</term>
<term>Killer Cells, Natural</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Epstein-Barr Virus Infections</term>
<term>Lymphoma, T-Cell, Peripheral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Activation enzymatique</term>
<term>Apoptose</term>
<term>Cellules tueuses naturelles</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en">
<term>Herpesvirus 4, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr">
<term>Herpèsvirus humain de type 4</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Caspase 3</term>
<term>Poly(ADP-ribose) Polymerases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Caspase-3</term>
<term>Poly(ADP-ribose) polymerases</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en">
<term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Infections à virus Epstein-Barr</term>
<term>Lymphome T périphérique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Cellules tueuses naturelles</term>
<term>Infections à virus Epstein-Barr</term>
<term>Lymphome T périphérique</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Epstein-Barr Virus Infections</term>
<term>Killer Cells, Natural</term>
<term>Lymphoma, T-Cell, Peripheral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Bevacizumab</term>
<term>Blotting, Western</term>
<term>Humans</term>
<term>Injections, Intraperitoneal</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, SCID</term>
<term>Middle Aged</term>
<term>Neoplasm Transplantation</term>
<term>Transplantation, Heterologous</term>
<term>Tumor Cells, Cultured</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Bévacizumab</term>
<term>Cellules cancéreuses en culture</term>
<term>Humains</term>
<term>Injections péritoneales</term>
<term>Mâle</term>
<term>Souris</term>
<term>Souris SCID</term>
<term>Technique de Western</term>
<term>Transplantation hétérologue</term>
<term>Transplantation tumorale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Natural killer (NK) lymphomas occurring more frequently in the Far East and South America respond poorly to anthracycline-based regimens. Here we report an in vivo NK lymphoma xenograft (NK-S1) derived from the testicular metastasis of a patient with an extranodal NK lymphoma (nasal type). The NK-S1 xenograft, established in severe combined immune deficient (SCID) mice retained the same imunophenotypic features as the original tumor. NK-S1 disseminated intra-abdominally to the testis, intestine and liver. Although doxorubicin, rapamycin, bevacizumab, rapamycin-doxorubicin, and bevacizumab-doxorubicin had no effects on the growth of subcutaneous NK-S1 xenografts, intraperitoneal (IP) delivery of cyclophosphamide caused complete tumor regression; this tumor regression was associated with apoptosis, upregulation of activated caspase-3, and cleaved Poly(ADP-ribose) polymerase (PARP). In an IP model of NK lymphoma, cyclophosphamide also prolonged the survival of mice and potently inhibited tumor dissemination and ascites formation. Our data suggest that the NK-S1 xenograft is a useful tool for screening preclinical drugs, and cyclophosphamide may be a useful drug for the treatment of this disease.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18452087</PMID>
<DateCompleted>
<Year>2008</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>01</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1029-2403</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>49</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2008</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia & lymphoma</Title>
<ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation>
</Journal>
<ArticleTitle>An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.</ArticleTitle>
<Pagination>
<MedlinePgn>1161-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/10428190802043879</ELocationID>
<Abstract>
<AbstractText>Natural killer (NK) lymphomas occurring more frequently in the Far East and South America respond poorly to anthracycline-based regimens. Here we report an in vivo NK lymphoma xenograft (NK-S1) derived from the testicular metastasis of a patient with an extranodal NK lymphoma (nasal type). The NK-S1 xenograft, established in severe combined immune deficient (SCID) mice retained the same imunophenotypic features as the original tumor. NK-S1 disseminated intra-abdominally to the testis, intestine and liver. Although doxorubicin, rapamycin, bevacizumab, rapamycin-doxorubicin, and bevacizumab-doxorubicin had no effects on the growth of subcutaneous NK-S1 xenografts, intraperitoneal (IP) delivery of cyclophosphamide caused complete tumor regression; this tumor regression was associated with apoptosis, upregulation of activated caspase-3, and cleaved Poly(ADP-ribose) polymerase (PARP). In an IP model of NK lymphoma, cyclophosphamide also prolonged the survival of mice and potently inhibited tumor dissemination and ascites formation. Our data suggest that the NK-S1 xenograft is a useful tool for screening preclinical drugs, and cyclophosphamide may be a useful drug for the treatment of this disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Loong</LastName>
<ForeName>Susan Li Er</ForeName>
<Initials>SL</Initials>
<AffiliationInfo>
<Affiliation>Division of Cellular and Molecular Research, Department of Radiation Oncology, National Cancer Centre, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hwang</LastName>
<ForeName>Jacqueline Siok Gek</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lim</LastName>
<ForeName>Soon-Thye</ForeName>
<Initials>ST</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yap</LastName>
<ForeName>Swee Peng</ForeName>
<Initials>SP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tao</LastName>
<ForeName>Miriam</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chong</LastName>
<ForeName>Tsung-Wen</ForeName>
<Initials>TW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tan</LastName>
<ForeName>Leonard Hwan Cheong</ForeName>
<Initials>LH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huynh</LastName>
<ForeName>Hung</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Leuk Lymphoma</MedlineTA>
<NlmUniqueID>9007422</NlmUniqueID>
<ISSNLinking>1026-8022</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8N3DW7272P</RegistryNumber>
<NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C505409">Casp3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020031" MajorTopicYN="N">Epstein-Barr Virus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016411" MajorTopicYN="N">Lymphoma, T-Cell, Peripheral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011065" MajorTopicYN="N">Poly(ADP-ribose) Polymerases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2008</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2008</Year>
<Month>11</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2008</Year>
<Month>5</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">18452087</ArticleId>
<ArticleId IdType="pii">792728827</ArticleId>
<ArticleId IdType="doi">10.1080/10428190802043879</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Singapour</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Chong, Tsung Wen" sort="Chong, Tsung Wen" uniqKey="Chong T" first="Tsung-Wen" last="Chong">Tsung-Wen Chong</name>
<name sortKey="Huynh, Hung" sort="Huynh, Hung" uniqKey="Huynh H" first="Hung" last="Huynh">Hung Huynh</name>
<name sortKey="Hwang, Jacqueline Siok Gek" sort="Hwang, Jacqueline Siok Gek" uniqKey="Hwang J" first="Jacqueline Siok Gek" last="Hwang">Jacqueline Siok Gek Hwang</name>
<name sortKey="Lim, Soon Thye" sort="Lim, Soon Thye" uniqKey="Lim S" first="Soon-Thye" last="Lim">Soon-Thye Lim</name>
<name sortKey="Tan, Leonard Hwan Cheong" sort="Tan, Leonard Hwan Cheong" uniqKey="Tan L" first="Leonard Hwan Cheong" last="Tan">Leonard Hwan Cheong Tan</name>
<name sortKey="Tao, Miriam" sort="Tao, Miriam" uniqKey="Tao M" first="Miriam" last="Tao">Miriam Tao</name>
<name sortKey="Yap, Swee Peng" sort="Yap, Swee Peng" uniqKey="Yap S" first="Swee Peng" last="Yap">Swee Peng Yap</name>
</noCountry>
<country name="Singapour">
<noRegion>
<name sortKey="Loong, Susan Li Er" sort="Loong, Susan Li Er" uniqKey="Loong S" first="Susan Li Er" last="Loong">Susan Li Er Loong</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001653 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001653 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:18452087
   |texte=   An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:18452087" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020